<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325856</url>
  </required_header>
  <id_info>
    <org_study_id>ABISAD-3</org_study_id>
    <nct_id>NCT02325856</nct_id>
  </id_info>
  <brief_title>Application of Bioimpedance Spectroscopy in Taiwan Dialysis Patients</brief_title>
  <official_title>Effect of Post-dialysis Weight Evaluated With Bioimpedance Spectroscopy on Dialysis Morbidities and Clinical Outcomes in Hemodialysis Patients: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>An Hsin QingShui Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nephrocare AsiaPacific</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>An Hsin QingShui Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A reasonable and simple algorithm was used to guide the dry weight determination with Body
      Composition Monitor with the principle of Bioimpedance Spectroscopy (BCM-BIS) and analyze the
      feasibility of this algorithm and evaluate the influence of BCM-BIS-guided fluid management
      on the incidence of dialysis morbidities and clinical outcomes in maintenance hemodialysis
      (MHD) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      298 MHD patients in 6 hemodialysis centers in Taiwan were enrolled in this randomized
      controlled study. All the participants were randomized into study group ( dry weight (DW)
      determined by BCM-BIS) and control group ( dry weight determined by clinical symptoms) with
      stratification by diabetes mellitus and centers. Body composition monitor based on
      bioimpedance spectroscopy (BCM-BIS) was performed monthly and concomitant biochemical data
      and clinical outcomes were collected. Intra-dialysis complications were recorded in every
      dialysis session. Primary outcome was all-cause hospitalization. Secondary outcomes included
      1) complications during DW adjustment 2) intra-dialysis morbidities 3) hypertension 4)
      mortality 5) acute fluid overload (AFO) or cardiovascular (CV)-related events. The clinical
      feasibility of the BCM-BIS algorithm was also inspected. Statistical methods: a software
      (SAS) 9.3 was used for statistical analysis in this study. R 3.0 was used for graphic
      presentation of parts of the results. Relative risk, incidence rate ratio and Fisher's exact
      test were used to compare the discrete outcomes in both groups. Survival analysis was used
      for time-related events. Repeated-measured and longitudinal data were analyzed with the
      generalized linear mixed model (GLMM) through the procedure for continuous variables (PROC
      MIXED) and for discrete variables (PROC GLIMMIX) in SAS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Hospitalization</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications During DW Adjustment</measure>
    <time_frame>1 year</time_frame>
    <description>we wanted to compared whether the dialysis-related complications are different when DW (dry weight) is adjusted, no matter according to BCM (body composition monitor) results or clinical judgement, in both groups. The result is expressed as the percentage of months in which complications happened when DW adjustment presented (using total months which DW adjustments are present as denominator).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Fluid Overload</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dry weight determined by clinical symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioimpedance Spectroscopy</intervention_name>
    <description>Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Clinical judgement</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        MHD patients with age ≥ 18 and dialysis vintage ≥ 3 months

        Exclusion Criteria:

          1. coronary stents or pacemaker implantation

          2. metallic devices in body, such as artificial joints or pins

          3. contralateral or bilateral amputations

          4. pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2014</study_first_posted>
  <results_first_submitted>June 24, 2015</results_first_submitted>
  <results_first_submitted_qc>July 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2015</results_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Body Composition Monitor</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Group</title>
          <description>Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
Bioimpedance Spectroscopy: Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Dry weight determined by clinical symptoms</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Group</title>
          <description>Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
Bioimpedance Spectroscopy: Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Dry weight determined by clinical symptoms</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="298"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="12.1"/>
                    <measurement group_id="B2" value="62.1" spread="11.5"/>
                    <measurement group_id="B3" value="62.4" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All-cause Hospitalization</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
Bioimpedance Spectroscopy: Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Dry weight determined by clinical symptoms</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Hospitalization</title>
          <units>hospitalizations per patient-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.44" upper_limit="0.61"/>
                    <measurement group_id="O2" value="0.54" lower_limit="0.46" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications During DW Adjustment</title>
        <description>we wanted to compared whether the dialysis-related complications are different when DW (dry weight) is adjusted, no matter according to BCM (body composition monitor) results or clinical judgement, in both groups. The result is expressed as the percentage of months in which complications happened when DW adjustment presented (using total months which DW adjustments are present as denominator).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
Bioimpedance Spectroscopy: Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Dry weight determined by clinical symptoms</description>
          </group>
        </group_list>
        <measure>
          <title>Complications During DW Adjustment</title>
          <description>we wanted to compared whether the dialysis-related complications are different when DW (dry weight) is adjusted, no matter according to BCM (body composition monitor) results or clinical judgement, in both groups. The result is expressed as the percentage of months in which complications happened when DW adjustment presented (using total months which DW adjustments are present as denominator).</description>
          <units>% of months in which compli</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>months when dry weight adjustment happen</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="816"/>
                <count group_id="O2" value="735"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.76"/>
                    <measurement group_id="O2" value="30.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
          <description>Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
Bioimpedance Spectroscopy: Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Dry weight determined by clinical symptoms</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lim Paik-Seong</name_or_title>
      <organization>Department of Nephrology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan</organization>
      <phone>886-4-26581919</phone>
      <email>jamespslim@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

